News

GlobalData on MSN18h
Enrolment concludes in Phase III trial of Dizal’s sunvozertinib for NSCLC
The trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.
USA News Group: With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 20, 2025 /PRNewswire/ -- USA ...
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
Virtual webinar on June 23, 2025 at 8:00 am ETNEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated ...
ConsumerAffairs17h
FDA approves twice-yearly injection for HIV prevention
FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...
Private-Sector Oncology May Be the Market’s Best-Understood Secret
Baystreet.ca News Commentary – Cancer drug prices are rising sharply, with Bloomberg reporting growing concern over ...